The psychedelic renaissance has already been catalysed by a number of Breakthrough Therapy Designations from the U.S. FDA. Now, other national regulators are demonstrating interest in accelerating psychedelic drug development, with a fresh programme in post-Brexit UK representing a new ‘fast-track’ route. This week we learned that London-based Small Pharma is the first psychedelics company (to our…


Previous articleMore Evidence of the Chemical Compound Variability in Magic Mushrooms
Next articleBeckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial Assessing Safety and Tolerability of Intranasal 5-MeO-DMT